{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:06Z","timestamp":1786119366869,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1097\/cco.0b013e32832f3ca3","type":"journal-article","created":{"date-parts":[[2009,8,3]],"date-time":"2009-08-03T05:07:01Z","timestamp":1249276021000},"page":"397-400","source":"Crossref","is-referenced-by-count":14,"title":["The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma"],"prefix":"10.1097","volume":"21","author":[{"given":"Lauren S","family":"Maeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana H","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210128","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A Revised European-American Classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"R2-3-20210128","article-title":"WHO classification of tumors of hematopoietic and lymphoid tissues. 4th ed","author":"Stein","year":"2008"},{"key":"R4-3-20210128","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1084\/jem.20080809","article-title":"Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis","volume":"205","author":"Brune","year":"2008","journal-title":"J Exp Med"},{"key":"R5-3-20210128","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/13.S1.44","article-title":"Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell\/histiocyte-rich B cell lymphoma","volume":"13","author":"R\u00fcdiger","year":"2002","journal-title":"Ann Oncol"},{"key":"R6-3-20210128","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","article-title":"Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma project on lymphocyte-predominant Hodgkin's disease","volume":"17","author":"Diehl","year":"1999","journal-title":"J Clin Oncol"},{"key":"R7-3-20210128","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/annonc\/9.suppl_5.S39","article-title":"Lymphocyte predominant Hodgkin's disease: pathology and clinical implication","volume":"9","author":"Franklin","year":"1998","journal-title":"Ann Oncol"},{"key":"R8-3-20210128","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semradonc.2007.02.004","article-title":"Nodular lymphocyte-predominant Hodgkin lymphoma","volume":"17","author":"Tsai","year":"2007","journal-title":"Semin Radiat Oncol"},{"key":"R9-3-20210128","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1200\/JCO.2003.01.079","article-title":"Lymphocyte predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection \u2013 a study of the French Society of Pediatric Oncology","volume":"15","author":"Pellegrino","year":"2003","journal-title":"J Clin Oncol"},{"key":"R10-3-20210128","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group","volume":"26","author":"Nogov\u00e1","year":"2008","journal-title":"J Clin Oncol"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.V101.2.420","article-title":"Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group","volume":"101","author":"Rehwald","year":"2003","journal-title":"Blood"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2007-03-078725","article-title":"Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)","volume":"111","author":"Schulz","year":"2008","journal-title":"Blood"},{"key":"R14-3-20210128","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","article-title":"Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial","volume":"101","author":"Ekstrand","year":"2003","journal-title":"Blood"},{"key":"R15-3-20210128","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood.V110.11.644.644","article-title":"Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD) [ASH Annual Meeting Abstracts]","volume":"110","author":"Horning","year":"2007","journal-title":"Blood"},{"key":"R16-3-20210128","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000177953","article-title":"Rituximab in lymphocyte-predominant Hodgkin disease","volume":"76","author":"Azim","year":"2009","journal-title":"Oncology"},{"key":"R17-3-20210128","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/10428199909169633","article-title":"Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti-CD20 monoclonal antibody) and interleukin-2","volume":"35","author":"Keilholz","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"R18-3-20210128","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent nonHodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"key":"R19-3-20210128","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood.V112.11.3059.3059","article-title":"Phase I\/II dose-escalation study of tositumomab and Iodine I 131 tositumomab for relapsed\/refractory classical or lymphocyte-predominant Hodgkin's lymphoma: feasibility and initial safety [ASH Annual Meeting Abstracts]","volume":"112","author":"Jacene","year":"2008","journal-title":"Blood"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCO.0b013e32832f3ca3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:59:47Z","timestamp":1786039187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-200909000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32832f3ca3","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}